CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: Implications for neurological outcomes of lysosomal storage disorder

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Calias, Pericles ^a   Papisov, Mikhail ^b,c,d   Pan, Jing ^a   Savioli, Nancy ^a   Belov, Vasily ^b,c,d   Huang, Yan ^a   Lotterhand, Jason ^a   Alessandrini, Mary ^a   Liu, Nan ^a   Fischman, Alan J ^c,d   Powell, Jan L ^a   Heartlein, Michael W ^a  

^a Shire Human Genetic Therapies Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; IODINE 124; RECOMBINANT ENZYME; RECOMBINANT IDURONATE 2 SULFATASE; UNCLASSIFIED DRUG; IDURONATE 2 SULFATASE; RADIOACTIVE IODINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOG; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG TRANSPORT; ENZYME DEFICIENCY; FEMALE; HISTOPATHOLOGY; HUNTER SYNDROME; ISOTOPE LABELING; LYSOSOME; MACACA FASCICULARIS; MALE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; SINGLE DRUG DOSE; SPINAL CORD; ANIMAL; DRUG EFFECT; ENZYME REPLACEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOUSE MUTANT; NERVE CELL; PATHOLOGY; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; MUS; PRIMATES;

ANIMALS; CENTRAL NERVOUS SYSTEM; DOGS; ENZYME REPLACEMENT THERAPY; HUMANS; IDURONATE SULFATASE; IMMUNOHISTOCHEMISTRY; INJECTIONS, SPINAL; IODINE RADIOISOTOPES; LYSOSOMES; MACACA FASCICULARIS; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS II; NEURONS; OLIGODENDROGLIA; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; SPINAL CORD; TISSUE DISTRIBUTION;

EID: 84862940707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030341     Document Type: Article

References (65)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ, (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
2. Brown PD, Davies SL, Speake T, Millar ID, (2004) Molecular mechanisms of cerebrospinal fluid production. Neuroscience 129: 957-970.
3. Laterra J, Goldstein GW, (2000) Ventricular organization of the cerebrospinal fluid: blood-brain barrier, brain edema, and hydrocephalus In: Kandel E, Schwartz JH, Jessel TM, editors. Principles of neural science New York McGraw-Hill pp. 1288-1301.
4. Pardridge WM, (2003) Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 3: 90-105, 151.
5. Boado RJ, Pardridge WM, (2010) Genetic engineering of IgG-glucuronidase fusion proteins. J. Drug Target 18: 205-211.
6. Boado RJ, Hui EK, Lu JZ, Pardridge WM, (2009) AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol 144: 135-141.
7. Boado RJ, Zhang Y, Wang Y, Pardridge WM, (2009) Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng 102: 1251-1258.
8. Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardridge WM, (2010) Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm 7: 237-244.
9. Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM, (2002) Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 4: 183-194.
10. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, et al. (2000) Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17: 266-274.
11. Barbu E, Molnar E, Tsibouklis J, Gorecki DC, (2009) The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv 6: 553-565.
12. Ghafoor VL, Epshteyn M, Carlson GH, Terhaar DM, Charry O, et al. (2008) Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm 64: 2447-2461.
13. Belverud S, Mogilner A, Schulder M, (2008) Intrathecal pumps. Neurotherapeutics 5: 114-122.
14. Soderquist RG, Mahoney MJ, (2010) Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics. Expert Opin Drug Deliv 7: 285-293.
15. Hsieh JC, Penn RD, (2006) Intrathecal baclofen in the treatment of adult spasticity. Neurosurg Focus 21: 1-6.
16. Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML, (2003) Complications of intrathecal baclofen pumps in children. Pediatr Neurosurg 39: 1-6.
17. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73.
18. Patel NK, Gill SS, (2007) GDNF delivery for Parkinson's disease. Acta Neurochir 97 (Suppl): 135-154.
19. Ballantyne JC, Carwood CM, (2005) Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev CD005178.
20. Kerr JZ, Berg S, Blaney SM, (2001) Intrathecal chemotherapy. Crit. Rev Oncol Hematol 37: 227-236.
21. Rieselbach RE, Di Chiro G, Freireich EJ, Rall DP, (1962) Subarachnoid distribution of drugs after lumbar injection. N Engl J Med 267: 1273-1278.
22. Ghersi-Egea JF, Finnegan W, Chen JL, Fenstermacher JD, (1996) Rapid distribution of intraventricularly administered sucrose into cerebrospinal fluid cisterns via subarachnoid velae in rat. Neuroscience 75: 1271-1288.
23. Proescholdt MG, Hutto B, Brady LS, Herkenham M, (2000) Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [14C]inulin in rat. Neuroscience 95: 577-592.
24. Rennels ML, Blaumanis OR, Grady PA, (1990) Rapid solute transport throughout the brain via paravascular fluid pathways. Adv Neurol 52: 431-439.
25. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA, (1985) Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 326: 47-63.
26. Meikle PJ, Hopwood JJ, Clague AE, Carey WF, (1999) Prevalence of lysosomal storage disorders. J Am Med Assoc 281: 249-254.
27. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, et al. (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121: e377-386.
28. Elaprase [package insert] (2010) Cambridge, MA Shire Human Genetic Therapies, Inc.
29. Begley DJ, Pontikis CC, Scarpa M, (2008) Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des 14: 1566-1580.
30. Tsai SY, Markus TM, Andrews EM, Cheatwood JL, Emerick AJ, et al. (2007) Intrathecal treatment with anti-Nogo-A antibody improves functional recovery in adult rats after stroke. Exp Brain Res182: 261-266.
31. Kakkis E, McEntee M, Vogler C, Le S, Levy B, et al. (2004) Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83: 163-174.
32. Fenstermacher J, Kaye T, (1988) Drug "diffusion" within the brain. Ann N Y Acad Sci 531: 29-39.
33. Chiro GD, Hammock MK, Bleyer WA, (1976) Spinal descent of cerebrospinal fluid in man. Neurology 26: 1-8.
34. Segal MB, (2005) Fluid compartments of the central nervous system. In: Zheng W, Chodobski A, editors. The blood-cerebrospinal fluid barrier Boca Raton, Chapman & Hall/CRC pp. 83-99.
35. Felice BR, Wright TL, Boyd RB, Butt MT, Pfeifer RW, et al. (2011) Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol 39: 879-892.
36. Garcia AR, Pan J, Lamsa JC, Muenzer J, (2007) The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 30: 924-934.
37. Kakkis ED, (2002) Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs 11: 675-685.
38. Hemsley KM, Hopwood JJ, (2009) Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int J Clin Pharmacol. Ther 47 (Suppl 1): S118-123.
39. Hamano K, Hayashi M, Shioda K, Fukatsu R, Mizutani S, (2008) Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue. Acta Neuropathol 115: 547-559.
40. Vedolin L, Schwartz IVD, Komlos M, Schuch A, Puga AC, et al. (2007) Evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys Am J Neuroradiol 28: 1029-1033.
41. Matheus MG, Castillo M, Smith JK, Armao D, Towle D, et al. (2004) Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 46: 666-672.
42. Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R, (2009) Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 154: 733-737.
43. Shihabuddin LS, Aubert I, (2010) Stem cell transplantation for neurometabolic and neurodegenerative diseases. Neuropharmacology 58: 845-854.
44. Passini MA, Lee EB, Heuer GG, Wolfe JH, (2002) Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 22: 6437-6446.
45. Cearley CN, Wolfe JH, (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 27: 9928-9940.
46. Luca T, Givogri MI, Perani L, Galbiati F, Follenzi A, et al. (2005) Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. Mol Ther 12: 669-679.
47. Consiglio A, Quattrini A, Martino S, Bensdadoun JC, Dolcetta D, et al. (2001) In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 7: 310-316.
48. Lattanzi A, Neri M, Maderna C, di Girolamo I, Martino S, et al. (2010) Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Hum Mol Genet 19: 2208-2227.
49. Davidson BL, Breakefield XO, (2003) Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4: 353-364.
50. Vite CH, Passini MA, Haskins ME, Wolfe JH, (2003) Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther 10: 1874-1881.
51. Wu X, Burgess SM, (2004) Integration target site selection for retroviruses and transposable elements. Cell Mol Life Sci 61: 2588-2596.
52. Woods NB, Muessig A, Schmidt M, Flygare J, Olsson K, et al. (2003) Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101: 1284-1289.
53. Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, et al. (2004) Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2: 2183-2190.
54. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, et al. (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302.
55. Kar S, Poirier J, Guevara J, Dea D, Hawkes C, et al. (2006) Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology. Neurobiol Aging 27: 199-210.
56. Hawkes C, Kar S, (2002) Insulin-like growth factor-II/Mannose-6-phosphate receptor in the spinal cord and dorsal root ganglia of the adult rat. Eur J Neurosci 15: 33-39.
57. Chen F, Vitry S, Hocquemiller M, Desmaris N, Ausseil J, et al. (2006) Alpha-L-Iduronidase transport in neurites. Mol Genet Metab 87: 349-358.
58. Muenzer J, Wraith JE, Beck M, Guigliani R, Harmatz P, et al. (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter Syndrome). Genet Med 8: 465-473.
59. Loening AM, Gambhir SS, (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2: 131-137.
60. Hudson HM, Larkin RS, (1994) Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 13: 601-609.
61. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH, (1998) High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 43: 1001-1013.
62. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, et al. (1997) Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 16: 145-158.
63. Papisov M, Belov V, Fischman A, Bonab A, Titus J, et al. (2010) PET imaging of protein pharmacokinetics in the CSF of rats and monkeys with I-124. J Nucl Med 51 (Suppl 2): 1751.
64. Voznyi YV, Keulemans JL, van Diggelen OP, (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 24: 675-680.
65. Garcia AR, Pan J, Lamsa JC, Muenzer J, (2007) The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 30: 924-934.